Target
NRAS
25 abstracts
Abstract
PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.Org: Cheminpharma,
Abstract
FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1 mutations: A phase 1B dose-expansion study.Org: Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Beijing Cancer Hospital, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, Jiangsu Province Hospital, Nanjing, Jiangsu, China, Sun Yat-Sen University Cancer Center, Guangzhou, China, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China, Fujian Cancer Hospital, Fuzhou, China, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Fudan University Shanghai Cancer Center, Shanghai, China, West China Hospital of Sichuan University, Chengdu, China, Shanghai Fosun Pharmaceutical Industrial Development CO., Ltd., Shanghai, China,
Abstract
An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1).Org: Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute/Tennessee Oncology, University of California Irvine, Comprehensive Cancer Centers of Nevada, Washington University School of Medicine in St Louis,
Abstract
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study.Org: University of Zürich Hospital, ISS AG, Integrated Scientific Services,
Abstract
Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.Org: The Comprehensive Cancer Center of Drum-Tower Hospital, The Third People's Hospital of Zhengzhou, The First Affiliated Hospital of Dalian Medical University,
Abstract
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.Org: Departments of Cutaneous Oncology and Immunology,
Abstract
A phase III, open-label, multicenter, randomized controlled trial of tunlametinib versus investigator-selected chemotherapy in patients with advanced NRAS-mutant melanoma who had previously received immunotherapy.Org: Drum-Tower Hospital,
Abstract
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.Org: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan,
Abstract
Refining risk stratification in CMML: A comprehensive assessment of the IPSS-M and other molecularly informed models.Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).Org: Center for Innovations in Quality Effectiveness and Safety, Houston, TX, VA Boston Healthcare System, Boston, MA, Baylor College of Medicine,
Abstract
Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.Org: Medical Oncology 1, Venetian Institute of Oncology-IRCCS, Padua, Padua, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Department of Medicine (DIMED) University of Padua and Veneto Institute of Oncology (IOV-IRCCS ),
Abstract
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).Org: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, New Brunswick, Roswell Park Comprehensive Cancer Center, Buffalo, IL, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, Division of Hematopathology, Mayo Clinic, Rochester, MN,
Abstract
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.Org: Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, Department of Oncology, University of Oxford, Oxford, United Kingdom, Division of Pathology and Data Analytics, University of Leeds, Leeds, United Kingdom, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom, Queen's University Belfast, Belfast, United Kingdom,
Abstract
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.Org: Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori – IRCCS Fondazione G. Pascale, Napoli, Italy, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Istituto Nazionale Tumori - IRCCS Fondazione Pascale, Medical Oncology Unit. Comprehensive Cancer Center. AUSL-IRCCS Reggio Emilia, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.Org: Skin Cancer Center, University Hospital Leipzig, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, Personalis, Inc.,
Abstract
Assessment of genomic profiling in patients with colorectal cancer treated in community oncology practices.Org: Compass Oncology, Ontada,
Abstract
Next generation sequencing (NGS) testing for cancer patients at a safety NET hospital.Org: Alameda Health System-Highland Hospital, Highland Hospital/Alameda Health Systems, Alameda Health Systems,
Abstract
The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,
Abstract
The genetics of transformation from myelodysplastic syndrome to secondary acute myeloid leukemia.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical Universityand Shandong Academy of Medical Sciences, Sino-US Diagnostics Lab,
Abstract
Prognostic biomarkers for survival in mucosal melanoma.Org: Massachusetts General Hospital/Harvard Medical School, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, MASS General Hospital BHX-1,
Abstract
Prognostic value of BRAF and RAS mutations in radically resected patients (pts) with stage I-III melanoma: Preliminary results from a retrospective study.Org: APSS Trento S.Chiara Hospital Oncology Unit, Trento, Italy, S.Chiara Hospital, Oncology Unit S. Chiara Hospital, Trento, Italy,
Abstract
Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.Org: Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, NY, India, Adana Acıbadem Hospital, Adana, Turkey, St Bartholomew's Hospital, London, United Kingdom, Fortis Cancer Institute, New Delhi, India, Imperial College London, London, United Kingdom,
Abstract
Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience.Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,